ArticleDevelopmental cell2020
Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications.
Article in Developmental cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 108 citations in OpenAlex.
- CRISPR/Cas9 Delivery Using Extracellular Vesicles.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Extracellular vesicles-mediated delivery of SpCas9 RNPs for therapeutic gene editing in Spinocerebellar Ataxia Type 3.Biomaterials · 2026Article
- Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives.MedComm · 2026Review
- Engineering human PEG10-based nanoparticles for RNA self-packaging, delivery and cancer therapy.Nature communications · 2026Article
- Metabolic Tagging of Tumour Extracellular Vesicles for Targeted Modulation of Dendritic Cells.Journal of extracellular vesicles · 2026Article
- Mechanisms and functions of large extracellular vesicle biogenesis.Nature cell biology · 2026Review
- Development of a Live-Cell Imaging Assay to Elucidate Spatiotemporal Dynamics of Extracellular Vesicle Fusion with Target Cells.Journal of extracellular vesicles · 2026Article
- Article
- Review
- Hijacking exosome biogenesis: viral glycoproteins as modular scaffolds for engineering functionalized extracellular vesicles.Nanoscale · 2026Article
- Harnessing extracellular vesicles for ischemic stroke management.Regenerative biomaterials · 2026Review
- Optimization of the VSV-G backbone for amino terminal fusion with nanobodies allowing its specific retargeting to HER2 receptors.Molecular therapy. Oncology · 2025Article
- Efficient Scaling up EV-AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy.Journal of extracellular vesicles · 2025Article
- Lineage Mapping of Extracellular Vesicles: What Cells Do They Come from and Where Do They Go?Advances in wound care · 2025Review
- Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025Review
- Fusogenic Nanoreactor-Based Detection of Extracellular Vesicle-derived miRNAs for Diagnosing Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Control of Physical and Biochemical Parameters Influencing Exogeneous Cargo Protein Association to Extracellular Vesicles Using Lipid Anchors Enables High Loading and Effective Intracellular Delivery.Journal of extracellular biology · 2025Article
- Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors.Nature communications · 2025Article
- Extracellular Vesicles as a Potential Therapy for Stroke.International journal of molecular sciences · 2025Review
- Targeted macrophage mannose receptor (CD206)-specific protein delivery via engineered extracellular vesicles.Heliyon · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Getting large macromolecules through the plasma membrane and endosomal barriers remains a major challenge. Here, we report a generalizable method of delivering proteins and ribonucleoproteins (RNPs) to cells in vitro and mouse liver tissue in vivo with engineered ectosomes. These ectosomes, referred to as "Gectosomes," are designed to co-encapsulate vesicular stomatitis virus G protein (VSV-G) with bioactive macromolecules via split GFP complementation. We found that this method enables active cargo loading, improves the specific activity of cargo delivery, and facilitates Gectosome purification. Experimental and mathematical modeling analyses suggest that active cargo loading reduces non-specific encapsulation of cellular proteins, particularly nucleic-acid-binding proteins. Using Gectosomes that encapsulate Cre, Ago2, and SaCas9, we demonstrate their ability to execute designed modifications of endogenous genes in cell lines in vitro and mouse liver tissue in vivo, paving the way toward applications of this technology for the treatment of a wide range of human diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.